drugset / Trial / NCT00445042
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Phase 2
Completed
71 enrolled
The Methodist Hospital Research Institute
Amgen · collabBayer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and toxicity levels of Dose Escalated Sorafenib in the treatment of patients with renal cancer.
Timeline
- Start
- 2005-11
- Primary completion
- 2008-09
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |